Table: Sumitomo Pharma -Q1 group results (IFRS)

Sumitomo Pharma

31/07/2025 07:33

Jul 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 3 months ended      3 months ended       Year to 
                Jun 30, 2025        Jun 30, 2024     Mar 31, 2026 
                   LATEST             YEAR-AGO          COMPANY   
                   RESULTS             RESULT          FORECAST   
  Sales            108.00               90.68           355.00    
                 (+19.1 pct)         (+19.8 pct)      (-11.0 pct) 
  Operating         20.40             loss 3.11          54.00    
                                                      (+87.5 pct) 
  Pretax
  Net               11.21               15.94            40.00    
                 (-29.7 pct)                          (+69.2 pct) 
  EPS Basic       28.21 yen           40.11 yen       100.68 yen  
  Ann Div                                NIL              NIL     
  -Q2 Div                                NIL              NIL     
  -Q4 Div                                NIL              NIL     
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T